Get the Stockscreener App
8.18
1.61%
0.13
Eupraxia Pharmaceuticals Inc stock is traded at $8.18, with a volume of 280.64K.
It is up +1.61% in the last 24 hours and down -4.55% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$8.05
Open:
$8.15
24h Volume:
280.64K
Relative Volume:
1.46
Market Cap:
$414.30M
Revenue:
-
Net Income/Loss:
$-29.42M
P/E Ratio:
-9.4164
EPS:
-0.8687
Net Cash Flow:
$-25.01M
1W Performance:
+0.74%
1M Performance:
-4.55%
6M Performance:
+61.98%
1Y Performance:
+90.68%
1-Day Range:
$7.97
$8.24
1-Week Range:
$7.97
$8.79
52-Week Range:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
8.18 | 407.72M | 0 | -29.42M | -25.01M | -0.8687 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug - Investing.com Nigeria
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug By Investing.com - Investing.com Australia
(EPRX.WT.A) Technical Pivots with Risk Controls - Stock Traders Daily
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Eupraxia Pharmaceuticals closes $63.2M public offering - Investing.com India
Eupraxia Pharmaceuticals closes $63.2M public offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals stock gains after $63M offering - Investing.com Nigeria
Eupraxia Pharmaceuticals stock gains after $63M offering By Investing.com - Investing.com UK
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness - TipRanks
Eupraxia Pharmaceuticals Closes $63.2 Million Offering - marketscreener.com
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - The Manila Times
Eupraxia Pharmaceuticals Announces Closing of US$63.2 - GlobeNewswire
Long Term Trading Analysis for (EPRX.WT.A) - Stock Traders Daily
Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact - TipRanks
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals Prices $55 Million Public Offering - marketscreener.com
Eupraxia Pharmaceuticals prices $55 million public offering - Investing.com Nigeria
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering - Investing.com India
Eupraxia Pharma Prices $55 Mln Offering Of Shares And Warrants; Stock Down - Nasdaq
US Stocks Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Eupraxia Prices $55 Mln Offering To Advance Diffusphere Pipeline - Nasdaq
Eupraxia Pharmaceuticals announces pricing of US $55 million public offering of common shares and pre-funded warrants - marketscreener.com
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline - TipRanks
Eupraxia Pharmaceuticals Announces Pricing Of US $55 Million Public Offering Of Common Shares And Pre-Funded Warrants - TradingView
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million - GlobeNewswire
Biotech raises $55M to advance new Eosinophilic Esophagitis drug - Stock Titan
Eupraxia Pharmaceuticals Announces Proposed Public Offering - Investing News Network
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline - TipRanks
(EPRX.WT.A) Stock Market Analysis - Stock Traders Daily
Will Eupraxia Pharmaceuticals Inc. stock maintain momentum in 2025Earnings Risk Report & Daily Profit Focused Stock Screening - mfd.ru
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Equity Trading Insights - Stock Traders Daily
Will Eupraxia Pharmaceuticals Inc. benefit from rising consumer demandJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - mfd.ru
What’s the beta of Eupraxia Pharmaceuticals Inc. stockQuarterly Earnings Report & Risk Managed Trade Strategies - mfd.ru
Rate Hike: What are Eupraxia Pharmaceuticals Incs recent SEC filings showingWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Eupraxia Pharmaceuticals Inc. a good stock for dollar cost averaging2025 Winners & Losers & Free Technical Pattern Based Buy Signals - mfd.ru
(EPRX) Stock Trading Blueprint (EPRX:CA) - Stock Traders Daily
Can Eupraxia Pharmaceuticals Inc. stock deliver sustainable ROEQuarterly Trade Report & Daily Profit Focused Stock Screening - mfd.ru
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
(EPRX.WT.A) Strategic Investment Guide - Stock Traders Daily
Risk Off: Is Eupraxia Pharmaceuticals Inc affected by consumer sentimentWeekly Earnings Recap & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Valuation Update: Can Eupraxia Pharmaceuticals Inc beat the S P 500July 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Is HBOS plc Preferred Security forming a double bottomWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8%What's Next? - MarketBeat
(EPRX.WT.A) Advanced Trading Insights - Stock Traders Daily
Eupraxia Pharmaceuticals (TSX:EPRX) Trades With S&P/TSX Index - Kalkine Media
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo Finance
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):